Top 3 Small Cap Biotech Stocks to Watch
With this context and industry outlook in mind, let's start our list of 10 best biotech stocks to buy for 2021.
| Stocks with the Most Momentum | ||
|---|---|---|
| ViacomCBS Inc. ( VIAC) | 91.25 | 56.5 |
| Carvana Co. ( CVNA) | 274.17 | 47.2 |
| Tesla Inc. ( TSLA) | 662.16 | 635.6 |
| Etsy Inc. ( ETSY) | 219.67 | 27.7 |
Four great pharmaceutical stocks
The following list outlines some suggested criteria to consider when choosing which biotech stocks to buy.
XBIT, BDSI, and ACRS are top for value, growth, and momentum, respectively. The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions.
Jeff Bezos-backed startup Nautilus Biotechnology set to go public via SPAC at $900M valuation. Nautilus Biotechnology, a Seattle-based biotech startup led by Isilon co-founder Sujal Patel, is the latest company to go public using a special purpose acquisition company, or SPAC.
Best Stocks To Buy For Beginners Right Now
Gainers
| Company | Price | % Change |
|---|---|---|
| DVN Devon Energy Corp | 24.03 | +8.54% |
| HES Hess Corp | 75.94 | +7.79% |
| MRO Marathon Oil Corp | 11.75 | +6.43% |
| SYF Synchrony Financial | 43.03 | +5.65% |
So, to sum it up, if you're asking yourself if now is a good time to buy stocks, advisors say the answer is simple, no matter what's happening in the markets: Yes, as long as you're planning to invest for the long-term, are starting with small amounts invested through dollar-cost averaging and you're investing in ...
Top 25 pharma companies by global sales
| # | Company | Growth ($m) |
|---|---|---|
| 1 | Pfizer Inc | 5969 |
| 2 | Novartis AG | 3829 |
| 3 | F. Hoffmann-La Roche Ltd | 1918 |
| 4 | Sanofi | 2386 |
Rankings
| Rank | Company | Market Cap in 2020 (USD billions) |
|---|---|---|
| 1 | Johnson & Johnson NYSE: JNJ | 399.99 |
| 2 1 | Roche SIX: ROG | 291.12 |
| 3 2 | Pfizer NYSE: PFE | 208.11 |
| 4 1 | Novartis NYSE: NVS | 202.09 |
At recent prices, shares of Pfizer have been trading at just 13.7 times the company's 2021 earnings expectations, and that's before factoring in potential coronavirus vaccine sales. ... The company's already on pace to meet this expectation with non-coronavirus revenue expected to rise 6% year over year in 2021.
Yet No Comments